Biomarkers Market By Type, By Application, By Services : Global Opportunity Analysis and Industry Forecast, 2024-2033

List of Tables

The global biomarkers market size was valued at $46.4 billion in 2023, and is projected to reach $134.2 billion by 2033, growing at a CAGR of 11.2% from 2024 to 2033.

Biomarkers are measurable indicators that provide essential information about biological processes, health conditions, or responses to therapeutic interventions. These markers, found in various bodily fluids, tissues, or even imaging data, play a crucial role in diagnostics, prognosis, and monitoring of diseases. They serve as objectifiable and quantifiable measures, aiding clinicians in assessing the presence, severity, and progression of illnesses. Biomarkers cover a broad spectrum, including proteins, nucleic acids, metabolites, and imaging parameters, reflecting the diverse nature of biological systems.

The biomarkers market is expected to register significant growth during the forecast period owing to a rise in incidence of chronic diseases and high adoption of the biomarkers in the drug development process.

The rise in incidence of chronic diseases has emerged as a pivotal driver propelling the growth of the biomarkers market. In recent years, there has been a noteworthy surge in the prevalence of conditions such as cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders globally. For instance, according to the 2024 report by World Health Organization, it was estimated that over 35 million new cancer cases are expected to be diagnosed in 2050. This surge is attributed to several factors, such as sedentary lifestyles, unhealthy dietary habits, and an aging population. As chronic diseases continue to impose a substantial burden on healthcare systems, there is an increase in emphasis on early and accurate diagnosis for effective disease management.

Biomarkers, which are measurable indicators of biological processes or conditions, play a crucial role in disease diagnosis by providing valuable insights into the physiological state of an individual. Biomarkers facilitate early detection, risk assessment, and monitoring of disease progression, enabling timely intervention and personalized treatment strategies. For instance, Guardant Health, an American biotechnology firm, provides Guardant360 CDx test. Guardant360 CDx test is FDA-approved for complete genomic testing for all solid cancers. The test delivers comprehensive genomic results within 7 days of a basic blood test, helping doctors make informed treatment choices. Furthermore, technological advancements in genomics, proteomics, and metabolomics have broadened the range of biomarkers for clinical use, improving their effectiveness in diagnosis of various diseases. Thus, the rise in the incidence of chronic diseases is expected to drive the growth of the market.

The surge in adoption of biomarkers in the drug development process stands as a pivotal driver propelling the growth of the biomarkers market. Biomarkers, defined as measurable indicators of biological processes or responses to therapeutic interventions, have become indispensable tools in the drug development process. The ability of biomarkers to provide precise and real-time information about the physiological and molecular status of an organism has revolutionized the way pharmaceutical companies approach drug discovery and development. Biomarkers offer a means to objectively assess the efficacy, safety, and potential adverse effects of new drugs at various stages, from preclinical studies to clinical trials. This expedites the drug development timeline and enhances the probability of successful outcomes. For instance, according to the 2020 report by the National Library of Medicine, biomarkers are widely used at every stage of drug discovery and development. Utilization of biomarkers has a potential to make drug discovery, development, and approval processes more efficient. Thus, the rise in adoption of biomarkers in the drug discovery and development procedure is expected to contribute significantly to the growth of the market.

However, data security and privacy concerns have emerged as major concerns that restrain the growth of the market. The life sciences industry relies heavily on the collection, storage, and analysis of vast amounts of sensitive and confidential data, including patient records, clinical trial information, and genomic data. With the increase in digitization of healthcare processes and the adoption of advanced technologies, such as cloud computing and big data analytics, the risk of data breaches and unauthorized access has escalated. Thus, data security and privacy concerns are expected to restrain the growth of the market.

In addition, high development costs might restrain the growth of the market. The discovery and validation of biomarkers involve significant R&D costs. The high cost of developing and validating biomarkers negatively impacts the adoption of the biomarkers particularly in smaller companies.

The biomarkers market is segmented on the basis of type, application, service, and region. By type, the market is divided into efficacy biomarkers, safety biomarkers, and validation biomarkers. By application, the market is divided into risk assessment, development of molecular diagnostic, disease diagnosis, drug discovery & development, drug formulation, forensic application, and others.

By service, it is classified into pharmaceutical & sample preparation, assay development, biomarker validation & testing, and other services. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, and rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, rest of LAMEA)

The major players profiled in the report are GE Healthcare, Abbott Laboratories, Inc., Bio-Rad Laboratories, Epistem Ltd., Eisai Co. Ltd., Roche Diagnostics Limited, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Aushon Biosystem, and Siemens AG.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biomarkers market analysis from 2023 to 2033 to identify the prevailing biomarkers market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the biomarkers market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global biomarkers market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Criss-cross segment analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Market share analysis of players at global/region/country level
SWOT Analysis

Key Market Segments

By Type

Safety Biomarkers
Validation Biomarkers
Efficacy Biomarkers

By Application

Risk Assessment
Development of Molecular Diagnostic
Disease Diagnosis
Drug Discovery and Development
- Type
- Clinical Trial - Pre Clinical Phase and Phase 1
- Clinical Trial Phase 2
- Clinical Trial Phase 3
- Clinical Trial Commercial Phase
Drug Formulation
Forensic Application
Others

By Services

Sample Preparation
Assay Development
Biomarker Validation and Testing
Other Services

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- France
- Germany
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Bio-Rad Laboratories, Inc.
Thermo Fisher Scientific
Qiagen N.V
F. Hoffmann-La Roche AG
GE Healthcare
Revvity, Inc.
Abbott Laboratories
Siemens AG
Merck KGaA
Agilent Technologies Inc.

Product Code: A00021

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. High adoption of biomarkers in drug discovery and development process.
  - 3.4.1.2. Surge in prevalence of chronic diseases.
  - 3.4.1.3. Rise in adoption of biomarkers in forensic analysis.
- 3.4.2. Restraints
  - 3.4.2.1. High cost of development of biomarkers.
- 3.4.3. Opportunities
  - 3.4.3.1. Collaborative efforts by private and government organizations for development of biomarkers.

CHAPTER 4: BIOMARKERS MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Efficacy Biomarkers
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Safety Biomarkers
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Validation Biomarkers
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: BIOMARKERS MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Risk Assessment
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Development of Molecular Diagnostic
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Disease Diagnosis
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Drug Discovery and Development
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
- 5.5.4. Drug Discovery and Development Biomarkers Market by Type
  - 5.5.4.1. Clinical Trial - Pre Clinical Phase and Phase 1 Market size and forecast, by region
  - 5.5.4.2. Clinical Trial Phase 2 Market size and forecast, by region
  - 5.5.4.3. Clinical Trial Phase 3 Market size and forecast, by region
  - 5.5.4.4. Clinical Trial Commercial Phase Market size and forecast, by region
5.6. Drug Formulation
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country
5.7. Forensic Application
- 5.7.1. Key market trends, growth factors and opportunities
- 5.7.2. Market size and forecast, by region
- 5.7.3. Market share analysis by country
5.8. Others
- 5.8.1. Key market trends, growth factors and opportunities
- 5.8.2. Market size and forecast, by region
- 5.8.3. Market share analysis by country

CHAPTER 6: BIOMARKERS MARKET, BY SERVICES

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Sample Preparation
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Assay Development
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Biomarker Validation and Testing
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
6.5. Other Services
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country

CHAPTER 7: BIOMARKERS MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Application
  - 7.2.3.1. North America Drug Discovery and Development Biomarkers Market by Type
- 7.2.4. Market size and forecast, by Services
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Type
  - 7.2.5.1.2. Market size and forecast, by Application
  - 7.2.5.1.3. Market size and forecast, by Services
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Type
  - 7.2.5.2.2. Market size and forecast, by Application
  - 7.2.5.2.3. Market size and forecast, by Services
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Type
  - 7.2.5.3.2. Market size and forecast, by Application
  - 7.2.5.3.3. Market size and forecast, by Services
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Application
  - 7.3.3.1. Europe Drug Discovery and Development Biomarkers Market by Type
- 7.3.4. Market size and forecast, by Services
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. UK
  - 7.3.5.1.1. Market size and forecast, by Type
  - 7.3.5.1.2. Market size and forecast, by Application
  - 7.3.5.1.3. Market size and forecast, by Services
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Type
  - 7.3.5.2.2. Market size and forecast, by Application
  - 7.3.5.2.3. Market size and forecast, by Services
  - 7.3.5.3. Germany
  - 7.3.5.3.1. Market size and forecast, by Type
  - 7.3.5.3.2. Market size and forecast, by Application
  - 7.3.5.3.3. Market size and forecast, by Services
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Type
  - 7.3.5.4.2. Market size and forecast, by Application
  - 7.3.5.4.3. Market size and forecast, by Services
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Type
  - 7.3.5.5.2. Market size and forecast, by Application
  - 7.3.5.5.3. Market size and forecast, by Services
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Type
  - 7.3.5.6.2. Market size and forecast, by Application
  - 7.3.5.6.3. Market size and forecast, by Services
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Application
  - 7.4.3.1. Asia-Pacific Drug Discovery and Development Biomarkers Market by Type
- 7.4.4. Market size and forecast, by Services
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Type
  - 7.4.5.1.2. Market size and forecast, by Application
  - 7.4.5.1.3. Market size and forecast, by Services
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Type
  - 7.4.5.2.2. Market size and forecast, by Application
  - 7.4.5.2.3. Market size and forecast, by Services
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Type
  - 7.4.5.3.2. Market size and forecast, by Application
  - 7.4.5.3.3. Market size and forecast, by Services
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Type
  - 7.4.5.4.2. Market size and forecast, by Application
  - 7.4.5.4.3. Market size and forecast, by Services
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Type
  - 7.4.5.5.2. Market size and forecast, by Application
  - 7.4.5.5.3. Market size and forecast, by Services
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Type
  - 7.4.5.6.2. Market size and forecast, by Application
  - 7.4.5.6.3. Market size and forecast, by Services
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Application
  - 7.5.3.1. LAMEA Drug Discovery and Development Biomarkers Market by Type
- 7.5.4. Market size and forecast, by Services
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Type
  - 7.5.5.1.2. Market size and forecast, by Application
  - 7.5.5.1.3. Market size and forecast, by Services
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Type
  - 7.5.5.2.2. Market size and forecast, by Application
  - 7.5.5.2.3. Market size and forecast, by Services
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Type
  - 7.5.5.3.2. Market size and forecast, by Application
  - 7.5.5.3.3. Market size and forecast, by Services
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Type
  - 7.5.5.4.2. Market size and forecast, by Application
  - 7.5.5.4.3. Market size and forecast, by Services

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. Abbott Laboratories
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. Agilent Technologies Inc.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Bio-Rad Laboratories, Inc.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. GE Healthcare
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
9.5. Siemens AG
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.5.7. Key strategic moves and developments
9.6. Thermo Fisher Scientific
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. Qiagen N.V
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
9.8. Merck KGaA
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.8.7. Key strategic moves and developments
9.9. F. Hoffmann-La Roche AG
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.9.7. Key strategic moves and developments
9.10. Revvity, Inc.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance